Stockscreener 앱 받기
8.5664
3.34%
-0.4036
전일 마감가:
$8.97
열려 있는:
$9
하루 거래량:
158.54K
Relative Volume:
0.14
시가총액:
$587.51M
수익:
-
순이익/손실:
$-96.66M
주가수익비율:
-3.9844
EPS:
-2.15
순현금흐름:
$-83.73M
1주 성능:
-1.37%
1개월 성능:
-21.89%
6개월 성능:
+54.27%
1년 성능:
-25.39%
1일 변동 폭
$8.55
$9.24
1주일 범위
$8.44
$9.54
52주 변동 폭
$2.86
$13.51
올레마 Stock (OLMA) Company Profile
명칭
Olema Pharmaceuticals Inc
전화
(415) 651-3316
주소
780 BRANNAN STREET, SAN FRANCISCO
OLMA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
8.56 | 615.65M | 0 | -96.66M | -83.73M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.25 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
635.23 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
441.03 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
829.86 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.66 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
올레마 Stock (OLMA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-08 | 개시 | Guggenheim | Buy |
| 2025-08-12 | 재확인 | Citigroup | Buy |
| 2024-04-02 | 개시 | Goldman | Buy |
| 2024-01-30 | 개시 | Citigroup | Buy |
| 2023-07-21 | 개시 | Oppenheimer | Outperform |
| 2023-05-05 | 개시 | CapitalOne | Overweight |
| 2023-02-22 | 개시 | Credit Suisse | Outperform |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-06-09 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-02-28 | 개시 | H.C. Wainwright | Neutral |
| 2021-12-07 | 재개 | Cowen | Outperform |
| 2020-12-14 | 개시 | Canaccord Genuity | Buy |
| 2020-12-14 | 개시 | Cowen | Outperform |
| 2020-12-14 | 개시 | JP Morgan | Overweight |
| 2020-12-14 | 개시 | Jefferies | Buy |
모두보기
올레마 주식(OLMA)의 최신 뉴스
Sector ETF performance correlation with Olema Pharmaceuticals Inc.Market Trend Report & AI Driven Price Forecasts - newser.com
Forecasting Olema Pharmaceuticals Inc. price range with options dataJuly 2025 Decliners & Fast Gaining Stock Strategy Reports - newser.com
What Fibonacci levels say about Olema Pharmaceuticals Inc. reboundJuly 2025 Analyst Calls & Technical Entry and Exit Alerts - newser.com
Is Olema Pharmaceuticals Inc. stock ready for breakoutVolume Spike & Risk Managed Trade Strategies - newser.com
How sustainable is Olema Pharmaceuticals Inc. stock dividend payoutJuly 2025 Market Mood & Real-Time Chart Pattern Alerts - newser.com
How to build a dashboard for Olema Pharmaceuticals Inc. stockWeekly Stock Summary & Verified Momentum Stock Alerts - newser.com
Pier Capital LLC Has $3.29 Million Position in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Why Olema Pharmaceuticals Inc. stock could rally in 2025July 2025 Price Swings & Verified Momentum Stock Alerts - newser.com
Will Olema Pharmaceuticals Inc. stock go up soonJuly 2025 PostEarnings & Long Hold Capital Preservation Tips - newser.com
Can Olema Pharmaceuticals Inc. stock double in next 5 yearsMarket Activity Report & Smart Swing Trading Techniques - newser.com
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap UpHere's Why - MarketBeat
How geopolitical tensions affect Olema Pharmaceuticals Inc. stockRate Hike & Daily Growth Stock Investment Tips - newser.com
Why Olema Pharmaceuticals Inc. stock is in analyst buy zoneQuarterly Trade Summary & Daily Technical Stock Forecast Reports - newser.com
Olema Pharmaceuticals Inc. stock momentum explainedWeekly Stock Recap & Verified Entry Point Signals - newser.com
News impact scoring models applied to Olema Pharmaceuticals Inc.Bull Run & Free Long-Term Investment Growth Plans - newser.com
Will Olema Pharmaceuticals Inc. continue its uptrendGap Down & High Yield Equity Trading Tips - newser.com
Will Olema Pharmaceuticals Inc. stock rally after Fed decisions2025 Short Interest & Advanced Swing Trade Entry Plans - newser.com
Has Olema Pharmaceuticals Inc. found a price floorJuly 2025 Update & Trade Opportunity Analysis - newser.com
Olema Pharmaceuticals, Inc. (OLMA) stock price, news, quote and history - Yahoo! Finance UK
Olema Pharmaceuticals to Present Phase 3 OPERA-02 Trial Details at SABCS 2025 - Quiver Quantitative
Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025 - The Manila Times
Olema (NASDAQ: OLMA) to present OPERA-02 Phase 3 palazestrant + ribociclib at SABCS 2025 - Stock Titan
올레마 (OLMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.21%
0.96%
자본화:
|
볼륨(24시간):